Bio-Rad Laboratories, Inc. Stock

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-25 pm EDT 5-day change 1st Jan Change
275.6 USD -0.94% Intraday chart for Bio-Rad Laboratories, Inc. -1.93% -14.65%
Sales 2024 * 2.71B Sales 2025 * 2.86B Capitalization 7.88B
Net income 2024 * 444M Net income 2025 * 509M EV / Sales 2024 * 2.66 x
Net cash position 2024 * 661M Net cash position 2025 * 1.24B EV / Sales 2025 * 2.32 x
P/E ratio 2024 *
18 x
P/E ratio 2025 *
15.8 x
Employees 8,030
Yield 2024 *
-
Yield 2025 *
-
Free-Float 66%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.94%
1 week-1.93%
Current month-20.32%
1 month-19.20%
3 months-12.87%
6 months-4.99%
Current year-14.65%
More quotes
1 week
272.35
Extreme 272.35
294.33
1 month
268.92
Extreme 268.916
350.32
Current year
268.92
Extreme 268.916
364.24
1 year
261.59
Extreme 261.59
473.50
3 years
261.59
Extreme 261.59
832.70
5 years
261.59
Extreme 261.59
832.70
10 years
102.71
Extreme 102.71
832.70
More quotes
Managers TitleAgeSince
Chief Executive Officer 74 88-12-31
Director of Finance/CFO 77 83-01-31
Chief Operating Officer 64 19-04-21
Members of the board TitleAgeSince
Director/Board Member 64 17-04-24
Founder 97 51-12-31
Director/Board Member 77 17-04-24
More insiders
Date Price Change Volume
24-04-25 275.6 -0.94% 164,776
24-04-24 278.2 -2.48% 209,104
24-04-23 285.3 +1.84% 250,549
24-04-22 280.1 +0.14% 217,079
24-04-19 279.7 -0.46% 294,125

Delayed Quote Nyse, April 25, 2024 at 04:00 pm EDT

More quotes
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
275.6 USD
Average target price
428.9 USD
Spread / Average Target
+55.62%
Consensus

Quarterly revenue - Rate of surprise